Platelet News and Research

RSS

Rivaroxaban shows promise in patients with acute coronary syndrome

Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.

11 Nov 2008

Arteriocyte awarded DARPA funding for company's blood pharming technology

Arteriocyte announced today a $1,950,000 award from DARPA for the company's Nanofiber Based System (NANEX) technology for the Production of Red Blood Cells project.

10 Nov 2008

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

Sunesis Pharmaceuticals, Inc. presented data from three clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), at the Chemotherapy Foundation Symposium held in New York on November 4-8.

7 Nov 2008

FDA approves Ranexa for the treatment of chronic angina

CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved a new, first line indication for Ranexa(R) (ranolazine extended-release tablets) for the treatment of chronic angina.

7 Nov 2008

New clinical study will help doctors assess abnormal bleeding

How do you know if you bleed normally? Scientists at The Rockefeller University Hospital's Center for Clinical and Translational Science (CCTS) aim to answer that question more definitively with the launch of an assessment tool designed to help physicians and researchers more accurately determine what is inside and outside the normal range of bleeding symptoms.

3 Nov 2008

Leukaemia drug may reverse multiple sclerosis brain damage

Scientists in Britain say a drug which was developed to treat leukaemia may also be a powerful new weapon against multiple sclerosis (MS).

23 Oct 2008

Further analysis from ATHENA study showed Multaq (Dronedarone) reduced risk of stroke in patients with atrial fibrillation

The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany.

3 Sep 2008

Pre-hospital treatment on the way to percutaneous coronary intervention

For patients with acute ST-segment-elevation AMI (STEMI) within 12 hours after symptom onset and with persistent ST-segment elevation, or new or presumednew left bundle-branch block with concomitant ST-segment elevation, restoring coronary blood flow as early as possible is the main goal of reperfusion strategies.

2 Sep 2008

Safety of antithrombotic treatment in acute coronary syndromes

The management of acute coronary syndromes (with or without ST segment elevation) requires the use of anticoagulants, antiplatelet agents (aspirin, clopidogrel and/or glycoprotein (GP) IIb/IIIa inhibitors), beta-blockers, thrombolytics in some cases, and revascularization / reperfusion.

2 Sep 2008

Overcoming poor response to standard oral antiplatelet agents

Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.

2 Sep 2008

Global study shows Telmisartan reduces outcome of cardiovascular death, heart attack or stroke

An international study led by Canadian researchers has found that telmisartan, a medication used to lower blood pressure, reduced the outcome of cardiovascular death, heart attack or stroke in people who are unable to tolerate a widely available and effective standard treatment.

31 Aug 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

Study reveals how blood flow force protects against atherosclerosis

Machines on cell surfaces, mechanical and lifeless as bed springs, protect blood vessels by responding to blood flow force, according to research published today in the Journal of Cell Biology. By sensing and reacting to force, such machines interfere with inflammatory pathways central to atherosclerosis, the cause of clogged arteries that lead to heart attack and stroke, the authors said. The next set of studies, already underway, seeks to "tweak" the process with the goal of designing a new class of therapies.

25 Aug 2008

FDA approves Nplate (romiplostim), first bone marrow stimulator for chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration has approved Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding.

24 Aug 2008

Scientists discover platelets play an important early role in promoting cerebral malaria

Platelets - those tiny, unassuming cells that cause blood to clot and scabs to form when you cut yourself - play an important early role in promoting cerebral malaria, an often lethal complication that occurs mostly in children.

18 Aug 2008

6 in every 100 patients die in hospital due to adverse drug reaction

Six of every 100 patients who die in hospital do so as a consequence of an adverse drug reaction or, in other words, a fatal reaction to medicines. Those are the conclusions of a research carried out at the Department of Medicine of the University of Granada, in collaboration with the Clinical Hospital San Cecilio of Granada, by Alfredo Jose Pardo Cabello and directed by Professors Emilio Puche Canas (Department of Pharmacology) and Francisco Javier Gomez Jimenez (Department of Medicine).

6 Jul 2008

Cancer cure in mice to be tested in humans

Scientists at Wake Forest University Baptist Medical Center are about to embark on a human trial to test whether a new cancer treatment will be as effective at eradicating cancer in humans as it has proven to be in mice.

30 Jun 2008

Cancer warning on diabetic ulcer gel

The U.S. watchdog the Food and Drug Administration (FDA) says a warning will be added to the label of a topical gel used to treat leg and foot ulcers which refuse to heal in diabetic patients.

9 Jun 2008

FDA announces label changes for Regranex - boxed warning

The U.S. Food and Drug Administration has announced the addition of a boxed warning to the label of Regranex Gel 0.01% (becaplermin) to address the increased risk of cancer mortality in patients who use 3 or more tubes of the product. Regranex is a topical cream indicated for the treatment of leg and foot ulcers that are not healing in diabetic patients.

8 Jun 2008

Reducing blockage fails to improve access to the bloodstream for kidney dialysis

Reducing early blockages in bloodstream access for kidney failure treatment does not increase the likelihood that the access will function adequately for long-term treatments, according to a study funded by the National Institutes of Health. Results were published May 14, 2008, in the Journal of the American Medical Association.

22 May 2008